Los Angeles Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Los Angeles Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.39K	Sell	353 -134,114	-100%	-$3.02M	﹤0.01%	2015
2025 Q4	$4.73M	Sell	134,467 -60,515	-31%	-$1.99M	0.02%	315
2025 Q3	$5.87M	Buy	+194,982	New	+$5.85M	0.02%	319
2022 Q1	–	Sell	-5,169	Closed	-$435K	–	1479
2021 Q4	$435K	Sell	5,169 -1,949	-27%	-$159K	﹤0.01%	1072
2021 Q3	$642K	Hold	7,118	–	–	﹤0.01%	948
2021 Q2	$679K	Sell	7,118 -2,886	-29%	-$301K	﹤0.01%	1028
2021 Q1	$1.14M	Sell	10,004 -8,777	-47%	-$1.19M	0.01%	837
2020 Q4	$2.6M	Buy	18,781 +101	+0.5%	+$12K	0.01%	578
2020 Q3	$1.53M	Buy	18,680 +3,360	+22%	+$279K	0.01%	656
2020 Q2	$1.2M	Buy	15,320 +2,260	+17%	+$150K	0.01%	785
2020 Q1	$580K	Buy	+13,060	New	+$678K	﹤0.01%	858
2019 Q4	–	Sell	-5,780	Closed	-$247K	–	1332
2019 Q3	$247K	Hold	5,780	–	–	﹤0.01%	1168
2019 Q2	$367K	Sell	5,780 -10,540	-65%	-$671K	﹤0.01%	1124
2019 Q1	$1.13M	Sell	16,320 -1,000	-6%	-$57.1K	0.01%	813
2018 Q4	$753K	Buy	17,320 +1,515	+10%	+$82.8K	﹤0.01%	836
2018 Q3	$1.21M	Buy	15,805 +1,440	+10%	+$117K	0.01%	803
2018 Q2	$1.1M	Sell	14,365 -380	-3%	-$24.5K	0.01%	859
2018 Q1	$752K	Buy	+14,745	New	+$743K	﹤0.01%	910

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Los Angeles Capital Management's RARE Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 100% in Q1 2026, selling an estimated $3.02M and leaving 353 shares worth $7.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

Los Angeles Capital Management first reported a position in RARE in Q1 2018 and has held it in 18 quarters since. The position peaked at $5.87M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Los Angeles Capital Management held 353 shares of Ultragenyx Pharmaceutical worth $7.39K as of Q1 2026.
Los Angeles Capital Management sold 134,114 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.02M.
Ultragenyx Pharmaceutical made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2015 holding.
Los Angeles Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and has held it in 18 quarters since.
Los Angeles Capital Management's Ultragenyx Pharmaceutical position peaked at $5.87M in Q3 2025.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.